Biotech Stocks in Motion - XOMA, Nanosphere, Isis Pharma, Halozyme Therapeutics, and Synta Pharma

LONDON, September 17, 2014 /PRNewswire/ --

The US markets on Tuesday, September 16, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,131.97, up 0.59% and the NASDAQ Composite closed at 4,552.76, up 0.75%. The S&P 500 finished the session 0.75% higher at 1,998.98. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 744.20, up 1.34%, with the index gaining 7.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: XOMA Corporation (NASDAQ: XOMA), Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

XOMA Corp.'s stock finished Tuesday's session 1.33% higher at $4.57. A total of 1.19 million shares were traded, which was below its three months average volume of 1.44 million shares. The stock vacillated between $4.41 and $4.60 during the session. Over the last one month, XOMA Corp.'s shares have advanced 6.28%. However, the stock has lost 5.77% in the previous three trading sessions and 32.10% since the beginning of the year. The company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $5.40 is greater than its 50-day moving average of $4.20. XOMA Corp.'s stock has a Relative Strength Index (RSI) of 53.27. Sign up and read the free notes on XOMA at:

www.Investor-Edge.com/XOMA-17Sep2014

On Tuesday, shares in Nanosphere Inc. fluctuated between $0.59 and $0.62 before ending the session 1.64% lower at $0.60. The stock reported a trading volume of 0.37 million shares, lower than its three months average volume of 1.22 million shares. Nanosphere Inc.'s shares have advanced 1.61% in the previous three trading sessions, while the stock has declined 36.27% in the last one month and 73.80% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $1.10 and $1.77, respectively. Moreover, shares of Nanosphere Inc. have an RSI of 28.36. The complimentary notes on NSPH can be downloaded as in PDF format at:

www.Investor-Edge.com/NSPH-17Sep2014

Isis Pharmaceuticals Inc.'s stock gained 1.70%, to close the day at $39.50. The stock recorded a trading volume of 1.60 million shares, below its three months average volume of 2.05 million shares. The company's shares oscillated between $38.20 and $39.66 during the session. Over the last one month and over the past three months, Isis Pharmaceuticals Inc.'s shares have gained 9.33% and 13.57%, respectively. However, the stock has fallen by 0.85% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 200-day moving average of $38.30 is above its 50-day moving average of $34.30. Additionally, the stock has an RSI of 55.03. Register for free on Investor-Edge and access the latest research on ISIS at:

www.Investor-Edge.com/ISIS-17Sep2014

On Tuesday, shares in Halozyme Therapeutics Inc. recorded a trading volume of 1.30 million shares, which was at par with the three months average volume. The stock ended the day at $9.04, up 0.56% from its previous day's closing of $8.99, and registered an intraday range of $8.75 and $9.11. Halozyme Therapeutics Inc.'s stock has lost 4.34% in the previous three trading sessions, 8.41% in the last one month, and 39.69% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $9.47 and $11.38, respectively. Furthermore, shares of Halozyme Therapeutics Inc.'s have an RSI of 41.26. The complete research on HALO is available for free at:

www.Investor-Edge.com/HALO-17Sep2014

Synta Pharmaceuticals Corp.'s stock plummeted 5.66% to end Tuesday's session at $3.67. The stock recorded a trading volume of 2.49 million shares, above its three months average volume of 1.61 million shares. The company's shares fluctuated between $3.65 and $3.90 during the session. Synta Pharmaceuticals Corp.'s shares have fallen by 29.96% since the start of this year. Further, the stock has lost 6.85% over the previous three trading sessions and 9.83% in the last one month. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $4.67 is above its 50-day moving average of $4.08. Additionally, the stock has an RSI of 40.82. Free in depth research on SNTA is available at:

www.Investor-Edge.com/SNTA-17Sep2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED